| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TAE684 | CCLE | pan-cancer | AAC | 0.1 | 0.03 |
| mRNA | AMG-706 | FIMM | pan-cancer | AAC | 0.35 | 0.03 |
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | 0.36 | 0.03 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.074 | 0.03 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.12 | 0.04 |
| mRNA | AG-014699 | GDSC1000 | pan-cancer | AAC | -0.076 | 0.04 |
| mRNA | AT-7519 | GDSC1000 | pan-cancer | AAC | -0.064 | 0.04 |
| mRNA | HLI 373 | CTRPv2 | pan-cancer | AAC | 0.073 | 0.04 |
| mRNA | BRD-K88742110 | CTRPv2 | pan-cancer | AAC | 0.075 | 0.04 |
| mRNA | CAY10618 | CTRPv2 | pan-cancer | AAC | -0.072 | 0.04 |